Country:
Years:
Category:

PT. Inovasi Bioproduk Indonesia

The major use of seaweed has been predominantly for human consumption. Call to increase consumption has long been made for seaweed gets highly regard as sustainable food potential. Besides its use in functional foods, seaweed also finds its way in processed, powdered forms used as hydrocolloids, texturing agents, and/ or stabilizers, for food, pharmacy, and cosmetic industries. The Global demand for particular use of seaweed in the form of empty capsule for instance, is expected to further increase in an annual growth rate averaging 7.3% per annum since 2016 and is projected to continue until 2026.
 Seaweed as the main input to Inobi’s production system has been becoming an important commodity to support the economy of the coastal area. Indonesia, commonly known as a country with the second longest shore line in the World, has huge potential. Combination of climatological aspect and ecology provides a perfect environment for seaweed cultivation. These facts make seaweed become one of Indonesia’s leading marine commodity in the Global market to date. Currently, Indonesia is the second best world’s seaweed producing country after Chile. Indonesia seaweed production in 2010 reached 3.082 million tons, exceeding the target set by the Ministry of Maritime Affairs and Fisheries (KKP) of 2.574 million tons. Further increase in production of 3.504 million tons in 2011, 5.1 million tons in 2012, 7.5 million tons in 2013. Indonesian seaweeds are commonly produced and exported in the form of dried seaweed and/or semi-finished product for example carrageenan, alginate and gelatine.
 Hard Capsules are solid preparations consisting of drugs in hard or soft shells that can dissolve. The shell is generally made from gelatin. Gelatin is a hydrolysis product from collagen that comes from the skin, tissue and bones of animals that are commonly used, namely from the bones of cattle or buffalo and pig bones. Hard capsule product from seaweed is an alternative gelatin capsule, important for Muslims, Jews, Hindus, Vegetarians and Others on dietary reason. The recent trends of increasing demand for plant based capsule husks finds its explanation not only in the aforementioned communities but more importantly in the changing lifestyle due to the improved awareness and the shift in the value of healthy life, whereby people exempt themselves from animal based- and derivate products and instead opt more for seaweed as healthier option.

Read More→

GeneFrontier Corporation

GeneFrontier Corporation (GFC) is a Japanese biotech company, which is one of the group companies of KANEKA Corporation. GFC is focusing on biopharmaceutical R&D support business with innovative products and services especially in the area of protein based biologics including antibodies.

Now, GFC is developing its proprietary technology for R&D of antibody therapeutics, which is a red hot in pharmaceutical industry. As our proprietary product and service, we launched PUREfrex and PUREfrexRD recently. Those are innovative technologies which can contribute to the R&D in pharmaceutical companies developing protein based biologics, such as therapeutic antibodies. It is a simple, fast, easy and effective screening system which can handle highly diversified library. It can remarkably accelerate R&D in pharmaceutical companies.

Our aim is to explore the potential of protein based biologics, and to contribute to the development of innovative therapeutics in healthcare industry through the partnership with pharmaceutical companies.

Read More→

AyoxxA

AyoxxA is a start-up company commercializing a novel technology platform developed at the National University of Singapore. This platform enables the measurement of a large number of different proteins and biomolecular analytes from a very small volume sample – so called “multiplexing” . In the field of genomic analysis, DNA microarrays have become a powerful tool. Yet, despite a rapidly growing multi-billion US$ market for protein analysis, comparable tools are not available at the protein level. AyoxxA addresses this need for multiplexed protein analysis with its platform technology of bead-based protein microarrays on a substrate biochip. This technology will benefit many disciplines, including biological research, pharmacological screening and medical diagnostics.

AyoxxA raised a Series A investment round of 4 Million US$ with several international venture capital companies as well as 1 Million US$ in grants in 2012. For 2013 AyoxxA is looking forward to closing a significantly larger multi-million US$ Series B investment.

Read More→

Apollo Medical Optics Inc.

The foundation for Apollo Medical Optics Inc. (AMO)’s technology is found at National Taiwan University, where inventors first began investigating the basics of medical optics. These researches eventually led to the development of the advanced technique used for the establishment of AMO’s specialized Optical Coherence Tomography (OCT) system. The difference in the AMO system is due to several factors: the system’s design, the implementation of the single-clad crystal fiber, the development and use of the system’s broadband light source, and the technique’s superior imaging quality. Due to the unique crystal fiber in place in AMO’s OTC system, it provides the AMO system’s images with stronger axial resolution and faster scanning speed when compared to other products. This fundamental technology has already successfully performed non-invasive scans on living patients, giving 3D images of the epidermis, part of the dermis, and the blood flow in capillaries within these areas. With a multidisciplinary and passionate team, AMO believes that the company can become the leading company of non-invasive technology in the world. Our first market will be focused on Mohs surgery (one of the skin cancer treatment), and it could apply our platform to the field of dermatology and pathology.

http://www.apollomedicaloptics.com/

Read More→

Repertoire Genesis, Inc.

Our primary mission is to contribute to super-personalized medicine by providing platform technology on the immune system. There are huge issues as follows: drugs do not always have the desired effect and adverse drug events are among the leading causes of death. Approximately, half of global drug sales, corresponding to $500 billion per year, are wasted on ineffective treatments and more than 2.2 million severe adverse drug events occur each year in the United States including more than 100,000 deaths. By identifying each patient’s drug targets with our company’s two analysis platforms, which are immuno-profiling and somatic gene mutation analyses, we could appropriately combine existing standardized therapies and develop personalized therapies.

We believe that our detailed understanding of the immune system, particularly that of the behaviors of T and B cells and disease-specific mutations, is key to developing personalized medicine.

http://www.repertoire.co.jp/

Read More→

BRAXX Biotech Co., Ltd.

Esophageal cancer is the eighth most common cancer in the world. There are over 450,000 new cases each year, and over 70% of whom are in Asia. In the esophageal cancer treatments, brachytherapy has advantages of high doses, high accuracy and high complete response rate, but its drawback is the fatal side effect. BRAXX Biotech develops an innovative solution to improve the therapeutic efficacy and avoid the side effects in traditional brachytherapy procedures. We dedicate to provide a better therapeutic environment for esophageal cancer patients.

Read More→

Genome Clinic

With the development of massively parallel next-generation sequencing that can analyze DNA samples at ultrahigh speed, the foundation for providing individual genome analysis to the general public at a realistic cost is being established. Databases have also been updated for genetic information on a large number of diseases. Although treatments and prevention methods might exist for a given disease, personal genome decoding can help devise medical interventions in accordance with the disease risk before actual onset of the disease, and thus help realize personalized medicine accordingly . When there are several members with a particular disease, such as cancer or cardiovascular disease, in one’s family, one might often get anxious about his/her own risk of developing that disease. Hiroki Sonehara, medical doctor at Chiba University Hospital, launched the project “Genome Clinic” in March 2017 as an original venture by Chiba University. This project offers a “medical checkup for personal genome,” where medical experts conduct individual genome analysis for prevention and early detection of disease in individuals from such afflicted families. So far, in this project, 59 genes in 27 diseases have been analyzed, for which the American College of Medical Genetics guideline has recommended understanding the risks and unveiling the actionable mutations. In Japan, this is the first attempt to evaluate multiple disease risks by conducting individual genome analyses by next-generation sequencing for general people who have not yet developed the disease some of their family members are afflicted with. The Genome Clinic will continue to conduct research aiming at price reduction for individual genome analysis and accuracy enhancement for disease risk judgement, thus improving analytical methods and social infrastructure for disease management.

Read More→

LPixel Inc.

LPixel, a spin-out startup from the University of Tokyo, is a leader in advanced image analysis software specialized in image data in life science field. The company was founded in March 2014 by three members working in the same research laboratory in the University of Tokyo. Since the establishment of the laboratory in 2000, the laboratory has been leading the image analysis technology in biological sciences. By integrating imaging technologies and the expertise in life science fields, LPixel developed a cloud-based image analysis platform specialized for life science images. The company is also developing a medical image analysis diagnostic support system designed to detect cancers and diseases by using their original artificial intelligence technologies. LPixel also provides a product which can detect unnatural parts such as cut and paste of images and processing in images included in academic papers in the life science area. LPixel is also involved in several major national projects including ImPACT and CREST to support the advancement of core image analysis technologies.

Read More→